Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company specializing in production and commercialization of gene therapies to cure eye diseases and developing a vaccine for COVID-19, announced that Research professionals at Indian Council of Medical Research (ICMR)-National Institute of Virologyfound that COVAXIN could potentially reflect high effectiveness against the Brazilian strain of SARS-CoV-2.
At last check-in premarket trading, shares of Ocugen Inc. (OCGN) were down -11.93% at $13.81. OCGN’s stock gained 23.76% to close Monday’s session at $15.68.In the past 12 months, the company’s stock has advanced 4566.67%, and in the last one week, the stock has moved up 35.29%. Furthermore, the company has a current market of $2.93 billion and its outstanding shares stood at 188.17 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Read More
- Looking For The Best Stocks To Buy For 2021? 3 Electric Vehicle Stocks To Watch
- Top 3 Cosmetics Stocks in the market
About Covaxin
COVAXIN is being developed in collaboration with the Indian Council of Medical Research (ICMR) – National Institute of Virology (NIV). COVAXIN consists of high levels of purification and inactivated vaccine that is produced using a Vero cell manufacturing platform with a safety track record exceeding 300 million doses distributed.
The vaccines generates a strong immune response against multiple antigens and has been successful in generating memory T cell responses, for its several epitopes, depicting longevity and a fast antibody response to potential infections in the future. The published data demonstrates higher safety profile compared to available data for various other vaccines. COVAXIN can be stored at a temperature between 2-8⁰C and is packaged in multi-dose vials.
The second interim results of the Phase 3 clinical trial depicted, COVAXIN showed 78% overall efficacy and 100% in serious COVID-19 disease. In accordance to ICMR studies, Covaxin was effective in neutralizing various SARS-CoV-2 variants including (B.1.617 (India, double mutant), B.1.1.7 (United Kingdom), B.1.1.28 (Brazil P2), and heterologous strain) in an in-vitro plaque reduction neutralization assay.
In April, India’s Bharat Biotech confirmed Covaxin capacity expansion to be increased to 700 million doses per annum. First interim data announced in March depicted a clinical efficacy of 81% for prevention of COVID-19 in those without previous infection after the second dose.
Conclusion.
COVAXIN has shown strong results in all the studies conducted to date. Furthermore, a high efficacy rate of the vaccine combined with a high safety profile has been seen beneficial for the pandemic, however, OCGN stock was declining 11.93% at last check, as the stock stabilizes.